Artrya Limited (ASX:AYA), a medical technology company focused on commercialising its patented AI platform that detects key coronary artery disease imaging markers, has entered its first commercial agreement in Australia with The Cardiac Centre NSW and The Cardiac CT Centre NSW, based in the Illawarra and South Coast of New South Wales.
Highlights:
- First commercial agreement in Australia with The Cardiac Centre NSW with a 12-month agreement for use of Artrya’s Salix® Coronary Anatomy software for the diagnosis of cardiovascular disease
- Cardiovascular imaging specialists will use Salix to assess patients across four specialist cardiac centres in Wollongong, Shellharbour, Bowral and Nowra
- Successful progression from evaluating Salix Coronary Anatomy during a testing phase to commercial agreement with first revenues expected in Q4 FY24.
Commentary:
Artrya CEO Mathew Regan said: “Artrya delivers what we believe is the most advanced and seamless technology platform on the market for the detection, diagnosis, and care of coronary artery disease, creating a new standard of care for the number one cause of death in the world.
This commercial agreement validates our strategy of entering new markets via evaluation periods, offering clinicians the opportunity to test and validate our technology, integrate it into their workflows, and experience firsthand the speed and accuracy of Salix in detecting heart disease compared to conventional methods.”